Menstrual hormone-induced cyclic thumb CMC instability and degeneration in women: a systematic review

Emily A. Parker*, Alex M. Meyer, Ignacio Garcia Fleury and Joseph A. Buckwalter V

Abstract
Background: Relaxin is a hormone which peaks during the luteal phase of the menstrual cycle, and a known collagenolytic promoter that has been shown to avidly bind tissues supporting the trapeziometacarpal (TMC) joint in women. We hypothesize a causal linkage between cyclic binding of relaxin to the supporting tissues of the female TMC joint; and to the earlier onset of more severe TMC osteoarthritis (OA) commonly seen in women.

Methods: A systematic literature review was performed per PRISMA guidelines, qualitatively and quantitatively assessing papers regarding relaxin–TMC joint stability interactions. The primary outcome variable was TMC joint degeneration/loss of function; the "late stage" consequences of relaxin-induced instability. The secondary outcome variable was presence of early signs of relaxin-induced instability; specifically asymptomatic TMC joint laxity in young women.

Results: In healthy young women, menstrual cycle relaxin peaks corresponded with asymptomatic TMC joint instability. Immunohistochemical studies of TMC arthroplasty patients showed avidly increased relaxin binding to supporting tissues around the TMC joint in women but not men. Demographic analysis of patients from the TMC arthroplasty studies show a predominantly female cohort, who were on average significantly younger than the male surgical patients.

Conclusions: Each relaxin peak during the menstrual cycle can target receptors on the soft tissues supporting the TMC joint, including—critically—the main stabilizing ligament: the anterior oblique. The cyclic instability is typically asymptomatic for years after menarche, but causes cumulative chondral microtrauma. This likely causes the early-onset, high severity TMC joint OA clinically pervasive among female patients at orthopedic hand clinics. Further research is indicated to develop risk assessment strategies and potential interventional options before and after the onset of hormonal laxity-induced OA.

Highlights

- It is widely recognized among hand surgeons that female patients present at a younger age for basal thumb osteoarthritis, with more severe degeneration.

*Correspondence: eaparker01@gmail.com

Department of Orthopedics and Rehabilitation, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa, IA 52242, USA

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

The unparalleled functional capacity of the thumb is facilitated by the unique structure of trapeziometacarpal (TMC) joint; a structure which increases the risk of OA development [1]. The TMC saddle joint has minimal intrinsic osseous stability, instead relying on attached ligaments for support, particularly the deep anterior oblique (palmar beak) ligament [1, 2]. The extensive number of relaxin binding sites around the female TMC joint incrementally decrease stability during child-bearing years [3–5]; post-menopausal women comprise 80% of the TMC joint OA patient population (Fig. 1) [6].

Female reproductive hormone relaxin, noted for facilitating parturition, is infrequently discussed outside of obstetrics. In non-pregnant women, relaxin peaks during the luteal phase of the menstrual cycle, and it is critical to note that in women the hormone triggers collagen degradation (Fig. 2). The heavily reinforced pubic symphysis exemplifies this; in non-pregnant women, approximately 2600 pounds of force are required to separate the joint [7]. During pregnancy, relaxin facilitates joint separation via extensive collagen degradation [7]. Accordingly, it is concerning that women have receptors for this powerful hormone beyond the reproductive tract (Fig. 3) [3, 5, 8].

Known female-specific locations of relaxin family peptide receptors (RXFPs)—the anterior cruciate ligament (ACL), TMC joint tissues—portend common female pathophysiology, such as ACL tears and basilar thumb OA (Fig. 4) [3–5]. Despite TMC joint osteoarthritis (OA) being degenerative and ACL ruptures being acute, both show the harms of relaxin activity in periarticular tissues [3–5]. TMC joint OA can severely impact completion of activities of daily living, and quality of life. The present review aims to assess literature on relaxin and TMC joint OA, to evaluate female OA risk and prevalence, elucidate the hormonal aspects of OA development, and identify any potential preventive (pre-osteoarthritic) or interventional (after the onset of arthritis) options for management.

Methods

Literature Search

This literature search was refined from a prior Joanna Briggs Institute (JBI) protocol-compliant scoping review search for a separate manuscript, with broad parameters including any English-language literature discussing both relaxin and any musculoskeletal pathology and/or injury. It was noted during this earlier review that a significant number of results addressed relaxin and the trapeziometacarpal joint in women, leading to the present, focused systematic review.

The initial scoping review search strategies were developed by the authors and an orthopedic health sciences librarian with expertise in literature reviews in June 2020,
Fig. 2 Legend, menstrual cycle hormone peaks and molecular effects: The sequence of hormone peaks for ovulatory menstrual cycles. Estrogen levels peak first, increasing expression of relaxin receptors in the body and increasing global synthesis of MMPs. The drop in estrogen triggers ovulation, and the remains of that ovarian follicle form the corpus luteum. As a temporary endocrine body, the corpus luteum secretes progesterone to prepare the endometrium for pregnancy and to sustain itself. It also synthesizes and releases relaxin, which binds receptors to activate MMPs recently upregulated by estrogen while also suppressing transcription of de novo collagen. Relaxin is active during the luteal phase, chiefly CD21-24.

Fig. 3 Legend, approximated cumulative lifetime instability: On average, in the US, women reach menarche (start having ovulatory menstrual cycles) at age 14, and enter menopause (cease having ovulatory menstrual cycles) at age 49. Individual ages can vary widely. The luteal phase when relaxin peaks, CD21 to CD24, is consistent among women. With an average of 13 menstrual cycles per year and 4 days of instability per cycle, over 35 years of menstrual activity, women are subject to roughly 5 years of TMC joint instability before reaching age 50.
with a repeat search for new literature relevant to the present review performed by the authors in December 2021. The initial search strategy was developed for MEDLINE. The first search string cast a wide net for any musculoskeletal injuries/pathology, with MeSH terms such as “hip injury” and “musculoskeletal injury”. Accompanying text words and phrases included “ligament” and “cartilage”. The second search string focused on female variations in relaxin hormone levels and activity, with MeSH terms such as “relaxin” and “relaxin receptor”. Accompanying text words and phrases included “cyclic hormonal variation” and “eumenorrheic”. The full search strategy for MEDLINE was as follows:

((((((((((((hip[MeSH Terms])) OR (hip joint[MeSH Terms])) OR (hip injury[MeSH Terms])) OR (hip dysplasia[MeSH Terms])) OR (femoroacetabular impingement[MeSH Terms])) OR (non-arthritic hip pain[Text Word])) OR (hip dysplasia[Text Word])) OR (femoroacetabular impingement[Text Word])) OR (cam lesion[Text Word])) OR (pincer lesion[Text Word])) OR (acetabular labral tear[Text Word])) OR (musculoskeletal injury[MeSH Terms])) OR (musculoskeletal injury[Text Word])) OR (ligament[Text Word])) OR (ligament[MeSH Terms])) OR (cartilage[MeSH Terms])) OR (cartilage[Text Word])) AND

(((relaxin[MeSH Terms]) OR (relaxin receptor[MeSH Terms])) OR (N(alpha) formyl-tyrosyl relaxin[MeSH Terms])) OR (hormone releasing intrauterine device[MeSH Terms])) OR (contraceptive agents[MeSH Terms])) OR (cycle, menstrual[MeSH Terms])) OR (dysmenorrhea[MeSH Terms])) OR (oligomenorrhea[MeSH Terms])) OR (amenorrhea[MeSH Terms])) OR (cyclic hormonal variation[Text Word])) OR (hormonal variation[Text Word]))

The search strategy was then adapted for EMBASE and CINAHL. Full search strategies for these databases are available upon request. The reference list of all included sources of evidence was screened for additional source materials via SCOPUS. All identified citations were uploaded to EndNote (EndNote X9.2, Clarivate Analytics, PA, USA) and duplicates removed by a combination of software screening and manual review. Titles and abstracts were then screened by two authors independently against the inclusion criteria, with animal-only studies being excluded. A full-text assessment was then performed to identify final inclusions.

Our initial scoping review screen yielded 82 included studies [8]. During the process of data extraction and analysis for the hip injury/relaxin scoping review, the
authors noted a number of quality research studies addressing relaxin and TMC joint laxity/osteoarthritis in women. This information was condensed and presented in the scoping review as supporting evidence, and thus was not explored as a topic of focus. The authors decided to perform a more stringent systematic review screen of the 82 scoping review papers, selecting for papers specifically addressing the relaxin–TMC relationship, and excluding any lower quality literature, such as case studies. This “re-screen” was again performed independently by two junior authors, with oversight from the senior authors, in accordance with PRISMA guidelines.

Statistical Analyses
Excel v.1808 (Microsoft Inc, Redmond, WA) was utilized to perform basic demographic calculations and all Student’s t tests. Student’s t tests were used to evaluate demographic data among all patients, specifically mean percent of female patients and mean patient age. They were also utilized for assessment of study outcome variables if data was present in sufficient amounts for an appropriately powered analysis.

Outcome Variables
This group of studies facilitated a multi-outcome assessment of the impact of elevated relaxin on the female TMC joint. Our primary outcome was TMC joint degeneration and loss of function, evaluated via patients being indicated for/undergoing arthroplasty and/or radiographic evidence of osteoarthritis; and functional assessments, such as patient-reported outcome scores (PROs) or findings on physical exam in the clinic. Needing arthroplasty and/or severe degeneration on imaging was considered the “late stage” of detrimental relaxin effects.

Our secondary outcome, early symptoms of relaxin effects, evaluated the extent and impact of relaxin-induced TMC joint laxity in younger women and/or women with no significant osteoarthritis of the joint. The extent of relaxin-induced laxity had to be measured by an objective observer in a clinical/research setting, looking at passive and active range of motion, ability to resist applied stress, etc. The impact of the relaxin-induced laxity could be determined via PROs, subject failure during research tests of strength/stability, or changes in physical task metrics during periods of peak vs. trough relaxin levels (i.e., significant changes in grip strength).

Other outcome variables assessed are important considerations in current relaxin research: further elucidating the extent to which serum relaxin concentration (SRC) reflects ongoing relaxin activity, given its preference for paracrine signaling; and the extent to which the physiological location and concentration of relaxin receptors indicates a location of relaxin activity, particularly when comparing males vs. females. Evaluating the first point, paracrine vs. endocrine activity of relaxin at various serum levels, was best assessed in women with documented detectable SRC measurements, known relaxin receptors around the TMC joint, and documentation of TMC joint health. The second point, evaluating the location of relaxin receptors versus locations of known relaxin activity in women and men, was well-suited for examination in the present review. Unlike the ACL, it is known that men have relaxin receptors present on TMC-adjacent tissue, yet do not experience early and/or severe osteoarthritis at rates similar to women.

Currently, the impact of relaxin has been well-documented from micro- to macro-level studies of ACL tears. The spectrum of evidence from molecular ACL degradation due to relaxin-activated MMPs, to population-level correlation of high relaxin levels and ACL tears, has constructed a sturdy base for future ACL/relaxin research. Therefore, with this review we aimed to determine what evidence is present or absent for TMC degeneration vs. relaxin levels; to see if pathways from relaxin peaks to injury or pathological state could be firmly established. We also assessed any proposed relaxin-focused interventions aiming to prevent injury/joint degeneration.

Study Quality
Study quality was evaluated by two authors independently, prior to reaching consensus scores on the Modified Coleman Criteria Scale (MCMS). Oversight was provided by the senior authors. As a group, the six included studies had an average MCMS of 21.6 ± 12.2 (range: 28 to 58); ranking poor quality per MCMS categories. However, two of the immunohistochemistry-focused studies were notable outliers [3, 4], with MCMS scores at least 14 points lower than the remaining four studies which contained clinical information. With the two outlying studies removed, the average MCMS was 50.3 ± 6.8 (range 44 to 58); ranking fair quality per MCMS categories.

Results
Of the 82 studies which met the criteria for inclusion in the authors’ prior scoping review [8], six studies met criteria for inclusion in the systematic review of relaxin vs. TMC joint pathology [3, 4, 9–12]. All six studies assessed the location/properties of relaxin receptors around the TMC joint [4, 11, 12], and/or the pathophysiologic effects of relaxin on the TMC joint both early in life (joint instability) and later in life (joint osteoarthritis) [3, 9–12]. Except for the case–control study by Em et al. [9], all included studies were prospective cohort designs [3, 4, 10–12]. Three studies focused on TMC arthroplasty patients [3, 4, 11], two
| Author, year | Title                                                                 | Study type             | Subject number (%F) | Mean age (years) | Subject factor(s) of interest                                                                 | Interventions and/or information collected                                                                 | Outcome variable(s)                                      |
|-------------|----------------------------------------------------------------------|------------------------|---------------------|------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| Clifton et al. 2014 | Detection of relaxin receptor in the dorsoradial ligament, synovium, and articular cartilage of the trapeziometacarpal joint | Prospective Cohort     | 15 (67%)            | F 59 (44–79), M 67 (56–79) | Undergoing TMC arthroplasty                                                                 | Collection of intraoperative tissue samples                                                                    | Immunostaining for relaxin receptor in dorsoradial ligaments and synovium                                      |
| Em et al. 2015 | Serum relaxin levels in benign hypermobility syndrome                  | Prospective Case Control | 88 (100%), 48 BJHS and 40 control | BJHS 25.2 ± 6.6, control 25.4 ± 7.1 | Women diagnosed with benign joint hypermobility syndrome by the research team                 | Assessment for hypermobility (via Beighton, Brighton), serum relaxin levels                                      | Average luteal SRC in women with BJHS vs controls (all female); the presence of specific musculoskeletal pathologies in each group |
| Lubahn et al. 2006 | Immunohistochemical detection of relaxin binding to the volar oblique ligament | Prospective cohort study | 8 (100%)            | Specified only as pre or perimenopausal | Non-menopausal women undergoing TMC arthroplasty, reconstruction of FCR                      | Collection of intraoperative tissue samples                                                                    | Presence of relaxin receptors in volar oblique ligament                                                        |
| Pokorny et al. 2000 | Self-reported oral contraceptive use and peripheral joint laxity    | Prospective Cohort     | 55 (100%), 25 control and 30 test | Range 20–25 | Women aged 20–25 on low-dose OCPS for 3 months (test group) or not taking contraceptives for 3+ months (control group) | Passive anterior translation of tibia, 5th DIP hyperextension, and 2nd PIP abduction/adduction | Laxity of knee and hand between oral contraceptive users and non-users                                            |
| Wolf et al. 2012 | Serum relaxin is correlated with relaxin receptors and MMP-1 in the anterior oblique ligament | Prospective Cohort     | 49 (61%)            | 62 (43–78) | Patients undergoing TMC arthroplasty, trapeziectomy, and ligament reconstruction               | Preoperative Beighton laxity score and serum relaxin level, intraoperative tissue sampling | Serum relaxin levels and relaxin receptor concentration in the anterior oblique ligament, relationship between MMP-1/MMP-13 and relaxin receptor location |
| Wolf, et al. 2013 | Relationship of serum relaxin to generalized and trapezial–metacarpal Joint laxity | Prospective Cohort     | 289 (53%)           | 47 (18–91) | Healthy volunteers                                                                                        | Screening for hypermobility (Beighton), TMC stress X-rays, SRC testing                                         | Serum relaxin levels and the effect on generalized and trapezial–metacarpal joint laxity                           |
focused on benign joint hypermobility syndrome (BJHS) [9, 12], while the final study assessed hormonal contraceptive (HCP) use (Table 1) [10].

The 504 total included subjects were distributed unevenly among the studies, with a range of 8–289 and an average of 84±105 subjects. The two largest studies, with 377 collective subjects, were assessing BJHS, while the three arthroplasty studies totaled 72 subjects (Table 1). In concordance with the preferential sex-specific manifestation of both BJHS and TMC OA, and as a result of artificial subject sex restriction by researchers, the average percent of female subjects per study was 80.2%±22.2%. Accordingly, as women tend to display symptoms of both conditions at a younger age, the average patient age was 44.0±19.4 years (Table 1).

Discussion
The present review aims to assess current literature regarding relaxin and TMC joint OA to better quantify the risk of pathophysiology among women, to determine a plausible mechanistic route for hormone related TMC OA development, and to pinpoint any promising strategies discussed for preventive or interventional purposes.

Relaxin Overview
Analytical discussion of joint-specific relaxin effects requires adequate global knowledge of the hormone; its endocrine properties, receptor behavior, and general homeostatic/physiologic roles. Relaxin (RLX) is a peptide hormone present in both sexes, with preferentially paracrine activity. In women, the corpus luteum synthesizes most but not all relaxin, and prostatic tissue synthesizes relaxin in men [13–15]. Average serum relaxin concentration (SRC) between sexes is similar when women are not experiencing luteal phase peaks, but with relaxin often acting locally, SRC does not consistently reflect the extent of hormone activity (Appendix: Table 3) [15, 16].

Accordingly, the location of relaxin family peptide receptors (RXFPs) is a sensitive indicator of relaxin’s physiological roles. From a sex-specific musculoskeletal consideration, RXFPs are uniformly present on certain articular/periarticular sites only in women, and RXFP expression is primed by estrogen and progesterone [14, 17–19]. Relaxin modulates ECM turnover, upregulating MMP-1/-13 (collagenases) and MMP-2/-9 (gelatinases) to degrade existing collagen while suppressing synthesis of new collagen via downregulation of transcription [14, 17–19]. Female relaxin levels peak in a temporal relationship with estrogen and progesterone menstrual cycle peaks (Fig. 2) [14, 20].

TMC OA Risk, Prevalence, and Severity per Sex
The first aim of this review was to assess the prevalence and risk of TMC OA development in women vs. men. Two of the three TMC arthroplasty studies were mixed sex, not restricted by researchers (Clifton et al. [3], and Wolf et al. [11]). Data from these 64 patients readily affirmed the sex-specific predominance of TMC OA, with the average percent of female vs. male patients being 64.0%±4.2% vs. 36.0%±4.2% (p<0.05). Only Clifton et al. (n=15) [3], provided average age per sex, and despite the small number of patients, nearly reached significance when evaluating if women undergo surgical intervention at an earlier age compared to men (age 59.0±7.8 years vs. 67.0±5.8 years, p=0.06).

Interestingly, all-subject analyses by Clifton et al. [3], showed no correlation between extent of relaxin receptor staining and sex; and a lack of significant difference in receptor concentration between men and women. Similarly, the Eaton–Littler score of TMC OA severity was not significantly associated with sex. However, their analysis showed clinically relevant significance after first sex-stratifying patients, and then evaluating the male and female patient group Eaton scores vs. extent of relaxin receptor staining. While the male group did not show significant results, the female group had a strongly positive correlation between Eaton score and amount of relaxin receptors.

This supports prior hypotheses that men have protective factors (lower circulating SRC, androgen-associated cartilage protection) preventing laxity as the joint’s binding capacity for relaxin increases [3]. Patients with severe disease, requiring trapeziectomy, were all female in this study; significantly younger at time of surgery compared to the standard male patient, with the need for trapeziectomy having strong positive correlations with Eaton score and RXFP1 concentration (Table 2) [3]. Wolf et al. [11] did not sex-stratify their results, although patients were majority female (61%) (Table 1). In this study, increased SRC was significantly, positively correlated with expression of RXFP1 and MMP-1 (collagenase) in TMC joint peri-articular tissues (Table 2).

The Hormonal Aspect of Trapeziometacarpal Joint Osteoarthritis Development
The pathophysiology of osteoarthritis development can be a complex, multifactorial route. In the present review, the studies of younger, hypermobile women without TMC joint pathology were valuable for understanding early patterns of instability. Markers of early-onset TMC joint OA could potentially be discerned from such research, be it physical exam measures or laboratory/radiographic testing results [9, 12]. In addition, studies of women exposed to exogenous hormonal influences such as OCPs (Pokorny et al. [10]) allow hormone fluctuations to be viewed as a modifiable variable. Finally, clarifying the molecular-level mechanisms of OA development was facilitated by three studies analyzing tissues extracted during TMC arthroplasty (Table 2) [3, 4, 11].
| Author, Year   | N (%F), Factor                                      | Interventions; Outcome Variables                                                                 | Hypotheses                                                                                                           | Study results |
|---------------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------|
| Clifton et al. 2014 | 15 (67%) TMC arthroplasty patients                  | Tissue sampling Immunostaining for RXFP1 in dorsoradial ligaments and synovium                    | RXFP1 will be present in tissues stabilizing the TMC joint; therefore, relaxin could impact joint stability            | Stratifying data by disease severity (Eaton–Littler score, timing to trapeziectomy) demonstrated a rapid pace of TMC degradation in women. Women were significantly younger at time of trapeziectomy, with a strong positive correlation of Eaton score and RXFP1 concentration. |
| Em et al. 2015 | 88 (100%) women; 48 with BJHS and 40 controls       | Assessment for hypermobility, SRC Average SRC in women with BJHS vs. controls                     | Elevated relaxin may play a role in certain physiologic manifestations of BJHS                                         | Serum relaxin levels of the BJHS group were non-significantly higher than controls (47.1 ± 20.3 pg/mL, 34.4 ± 22.1 pg/mL; p = 0.28). BJHS subjects had higher incidence of musculoskeletal pathologies, significantly (p < 0.05) arthralgia (33.3% vs. 25%), myalgia (55.6% vs. 27.5%), pes planus (5.78% vs. 30%), and hyperkyphosis (62.2% vs. 22.5%). The median relaxin levels were significantly greater in BJHS vs. control subjects with pes planus (33.3 vs. 16.4, p = 0.05) and/or hyperkyphosis (33.3 vs. 12.0, p < 0.005). |
| Lubahn et al. 2006 | 8 (100%) premenopausal women; TMC arthroplasty, FCR repair | Tissue Sampling Presence of relaxin receptors in volar oblique ligament                               | Female TMC OA prevalence may result from hormone-induced laxity of the volar oblique ligament. Relaxin is likely the hormone, it signals collagenases | Relaxin specifically bound all VOLS, with binding of cervical tissue > VOL > meniscal tissue. It was presumed that specific VOL binding of relaxin indicated cellular and/or extracellular matrix receptors. The lack of men presenting for treatment/study was noted. |
| Pokorny et al. 2000 | 55 (100%) women aged 20–25; 3 months with 30 on low-dose OCPs (test), 25 not | AP tibial translation, 5th DIP extension, 2nd PIP abduction, adduction Knee and hand laxity in OCP users vs. non-users | The average joint laxity of women on OCPs will be higher than women not on OCPs, due to the endogenous estrogen and progesterone | Joint laxity had no significant difference between groups, including when stratified by cycle day groups. The control group had non-significant greater knee laxity during CD23+, and 2nd PIP laxity during CD12–22. |
| Wolf et al. 2012 | 49 (61%) patients; TMC arthroplasty, trapeziectomy, ligament repair | Preoperative Beighton score and SRC, tissue sampling SRC, RXFP1 amount on anterior oblique ligament, relationship between MMP-1/MMP-13 and RXFP1 location | Relaxin is potentially involved in TMC joint laxity and eventual OA, via laxity of the anterior oblique ligament | Higher serum relaxin correlates with more thumb-area relaxin receptors and MMP-1 expression. Average mixed-sex expression levels were 3.73 pg/mL (0–9.45 pg/mL) for SRC, 5.23*10⁶ ag for RXFP1 receptor 0.022 ag for MMP-1, and 0.318 ag for MMP-3. Serum relaxin had significant relationships vs. log RXFP1 (p = 0.02) and vs. MMP-1 (p = 0.05). RXFP1, MMP-1, and MMP-3 were identified on the anterior oblique ligament. |
Table 2 (continued)

| Author, Year | N (%F), Factor | Interventions; Outcome Variables | Hypotheses | Study results |
|--------------|----------------|---------------------------------|------------|--------------|
| Wolf, J.M, Cameron, K.L. et al. 2013 | 289 (53%) healthy volunteers | Screening for hypermobility (Beighton), TMC stress X-rays, SRC testing SRC effect on general laxity, TMC joint laxity | High serum relaxin levels will correlate with laxity on TMC stress X-rays; it will also be associated with generalized joint laxity | 42% of subjects had detectable SRC; 63% of women and 37% of men. SRC was 2.5 × greater in women, significant in 40–59yo. The all-ages female vs. male average SRC was 2.6 ± 0.7 vs. 0.99 ± 2.4, p < 0.05; with less significance when limited to detectable values. Women, particularly younger age groups, were more lax. SRC-decetatable subjects had greater TM laxity, but only when controlling for age. Greater TM laxity was related to SRC, but so was younger age |
In examining hormone-associated TMC joint OA development in women, it was found that the risk of CMC joint subluxation had a significant positive correlation with detectable SRC in young, healthy women [12]. High serum relaxin was also found to significantly correlate with increased expression of relaxin receptors and the powerful relaxin-activated collagenase, MMP-1, in the anterior oblique ligament of the CMC joint; one of the joint’s major structural stabilizers [11]. This correlation of serum relaxin, relaxin receptors, and MMP-1 concentration was detected in tissue samples from female TMC arthroplasty patients [11]. Therefore, a reasonable hypothetical pathway for the development of hormone-associated TMC joint OA in women begins with elevated serum relaxin levels. High SRC increases TMC joint subluxation risk at a young age, with subluxations having the potential to acutely damage chondral cartilage and worsen ligament laxity. As high SRC levels persist, the supporting tissues of the TMC joint express more receptors, binding more relaxin, which activates the increased number of local collagenases. Collagen degradation of the soft tissues supporting the TMC joint would further worsen joint laxity, allowing for increased subluxations and abnormal weight loading detrimental to chondral cartilage health (Fig. 1).

Potential Preventive and/or Interventional Options to Mitigate Hormone-Related TMC Damage
Relaxin is necessary for correct function of the female reproductive tract, with undesirable extraneous effects beyond the reproductive organs, indicating that targeted, rather than systemic, treatments may be most promising [3]. It should be noted that hormonal contraceptive effects have been shown to reduce high relaxin levels and even decrease the rate of ACL tears among certain demographic groups, such as teen girls [21, 22]. However, only one study by Pokorny et al. [10] assessed impact of OCPs on laxity of the hand (second and fifth digits), and found no significant effects. Relaxin effects on women who are and are not using OCPs, in joints with well-established relaxin-mediated changes, such as the TMC joint, should be investigated.

The issue then becomes determining methods to locally decrease relaxin levels or counteract the pathophysiologic effects of relaxin peaks. Sustainability of the methods is a requirement, given that a woman reaching menarche and menopause at average ages, with average length menstrual cycles, will experience approximately 1800 days, or nearly 5 years, of lifetime luteal phase days during which her TMC joints could be at risk (Fig. 3). While OCP use may not be desirable for some women, a low-cost but labor-intensive option for management is menstrual cycle tracking. The increased joint laxity occurs over a set span of days (cycle day 21 to cycle day 24) on average [23–25]. Therefore, higher risk days can be identified by tracking menstrual cycles via calendar or any number of free phone, computer, and tablet applications [24, 25]. This is likely most useful for women who are already showing signs of TMC pathology. They can consult with occupational therapists regarding activity restrictions, supportive bracing, or other practices to adopt during this phase of the menstrual cycle. Intervening at the point of mild pathology would ideally prevent or slow the progressive development of subsequent damage (Fig. 1) [11, 25].

As relaxin receptors have synovial localization, the TMC joint synovial tissue is a target for focused treatment in the future [26–29]. In contrast to the female reproductive hormones, androgens such as testosterone actually have a collagen-protective effect which almost directly opposes the mechanism of collagenolysis triggered by relaxin [30, 31]. As testosterone already has local application mechanisms (topical cream, implanted subdermal pellets), consideration of a directly-applied androgen treatment during peak relaxin days for women with moderate-to-severe TMC pathology is worth consideration.

Perspectives and Significance
Common medical knowledge about relaxin is almost entirely limited to an obstetrical context, as is medical research about hormonal activity. It is critical to recognize that (1) Relaxin is physiologically active in women throughout a large span of their life, whether pregnant or not; and (2) Effects of relaxin are not limited to the reproductive organs in women; it is a powerful peptide hormone which modulates extracellular matrix turnover in numerous tissues throughout the body. A paradigm shift in medical care for women is necessary, to account for this significant physiological factor [8]. Early research should focus on discerning the tissues in which relaxin acts beyond the reproductive system; as the present review shows, a closer examination of female-predominant pathophysiology may yield answers here.

Limitations
This was a systematic review of small sample size studies pertaining to the TMC joint and relaxin, increasing the risk of bias. Furthermore, the studies assessed both relaxin (serum concentration levels vs. immunohistochemical staining of local receptors), and TMC joint degradation (radiographic evidence of OA vs. surgical evidence of OA) via different measures, some likely to be more valid and reliable than the others.

Conclusions
Each relaxin peak during the menstrual cycle can target receptors on the soft tissues supporting the TMC joint, including—critically—the main stabilizing ligament: the anterior oblique. The cyclic instability is
typically asymptomatic for years after menarche, but causes cumulative chondral microtrauma. This likely causes the early-onset, high severity TMC joint OA clinically pervasive among female patients at orthopedic hand clinics. Further research is indicated to develop risk assessment strategies and potential interventional options before and after the onset of hormonal laxity-induced OA.

### Appendix
See Table 3.

### Table 3 Cellular/molecular effects of relaxin-relevant literature findings

| Subcategory                        | Author, Year          | Findings                                                                                                                                                                                                 |
|------------------------------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Basic Properties of Relaxin**    | Goldsmith et al. 1995 [20] | Relaxin (RLX) is a peptide hormone in the insulin-like growth factor (IGF†) family                                                                                                                      |
|                                    | Grossman et al. 2010 [32] | Men and women have similar serum levels (400–500 pg/mL and 360–495 pg/mL), with luteal phase peaks in women                                                                                              |
|                                    | Lubahn et al. 2006 [4]  | Oral contraceptives decrease relaxin below a detectable serum level                                                                                                                                      |
|                                    | MacLennan et al. 1983 [13] | The major gene for relaxin in humans is H2; H2 relaxin binds relaxin family peptide receptor 1 and 2                                                                                                     |
|                                    | Powell et al. 2015 [14] | The corpus luteum produces most relaxin, but synthesis occurs in the endometrium, placenta, breast tissue, and prostate                                                                                 |
|                                    | Wolf et al. 2012 [11]   | Relaxin is biologically and immunologically active during pregnancy                                                                                                                                   |
|                                    | Wolf et al. 2013 [15]   | The capacity of relaxin to act locally means that serum levels do not always reflect activity                                                                                                             |
| **Properties of Relaxin Receptors**| Bryant-Greenwood et al. 1982 [25] | In humans, relaxin family peptide receptor-1 (RXFP‡) is most common, and has the highest affinity for H2 relaxin                                                                                  |
|                                    | Dragoo et al. 2003 [11] | Relaxin binds receptors in a time-, temperature-, and pH-dependent manner                                                                                                                                |
|                                    | Kapila et al. 1998 [18] | RXFP expression is primed by estrogen/progesterone in chondroblasts, fibrochondroblasts, myofibroblasts, and ligaments                                                                                |
|                                    | Kleine et al. 2017 [33] | Estrogen-primed receptors can show maximum response at RLX* levels 10–100 times lower than normal                                                                                                         |
|                                    | MacLennan et al. 1983 [13] | Estrogen, progesterone, and relaxin receptors modulate MMP§ transcription and post-translational modification                                                                                           |
|                                    | Powell et al. 2015 [14] | Radioreceptor location detection is a sensitive indicator of the physiological roles of RLX*                                                                                                               |
|                                    |                       | Relaxin receptors are detectable in anterior cruciate ligament (ACL¶) remnants of female, but not male, surgical patients                                                                            |
|                                    |                       | Relaxin binding was uniform, saturable, and specific to the synovial lining, stromal fibroblasts, and intima                                                                                             |
|                                    |                       | Relaxin receptors have been detected in the carpometacarpal joint of the thumb (1st CMC#) in arthroplasty patients                                                                                      |
|                                    |                       | The synovial lining, dorsoradial ligament, volar oblique ligament, and articular cartilage cells had receptors                                                                                           |
|                                    |                       | Concentration of RLX* receptors was significantly higher in women compared to men                                                                                                                      |
|                                    |                       | Relaxin receptors have been detected in the temporomandibular joint (TMJ**), on fibrochondrocytes and ligaments                                                                                      |
| **Functional, Physiologic Properties of Relaxin** | Ando et al. 1950 [34] | Relaxin controls extracellular matrix (ECM††) turnover by stimulating collagen degradation, and suppressing synthesis                                                                                   |
|                                    | Dragoo et al. 2003 [5] | Relaxin upregulates MMP§ production, specifically collagenases (MMP-1/-13) and gelatinases (MMP§-2/-9)                                                                                                  |
|                                    | Gale et al. 2003 [35]  | Active collagenases cleave tropocollagen, making it susceptible to subsequent denaturation by gelatinases                                                                                               |
|                                    | Goldsmith et al. 1995 [20] | The density and organization of collagen bundles, and total local collagen content decrease                                                                                                           |
|                                    | Grossman et al. 2010 [32] | MMP§s induced by relaxin degrade collagen at a nanoscale level, and macro-level effects are not always appreciable                                                                                     |
|                                    | Nose-Ogura et al. 2017 [21] | Relaxin has dose-dependent and differential functioning; its effects depend on location and presence of other hormones                                                                                 |
|                                    | Powell et al. 2015 [14] | There is a significant correlation between peak serum relaxin and peak serum progesterone levels                                                                                                         |
|                                    |                       | Intracellular relaxin activates MAPK‡‡ and PI3K§§, increasing cAMP¶¶ and triggering vasodilation via MMP§-2/-9                                                                                      |
|                                    |                       | Estrogen, progesterone, and relaxin binding synovial receptors upregulates inflammatory MMP§, increasing OA## risk                                                                                   |
|                                    |                       | Relaxin upregulates production of collagenases and gelatinases in ligaments and fibrocartilage                                                                                                         |
|                                    |                       | During parturition, relaxin binding pubic ligaments dissociates collagen, increases water uptake, and decreases viscosity                                                                             |
References

1. Sung JK, Akelman E. Thumb carpometacarpal arthritis. Tech Orthop. 2009;24(1):23–6.
2. Clifton K, Rodner CM, Drissi H, Wolf JM. Detection of relaxin receptor in the synovium and dorsal ligament of the trapeziometacarpal joint: Not a clinical study. J Hand Surg. 2012;37(8):7.
3. Clifton KB, Rodner C, Wolf JM. Detection of relaxin receptor in the dorsal ligament, synovium, and articular cartilage of the trapeziometacarpal joint. J Orthop Res. 2014;32(8):1061–7.
4. Lubahn J, Iancu D, Konieczko E, Cooney T. Immunohistochemical detection of relaxin binding to the volar oblique ligament. J Hand Surg Am. 2006;31(1):80–4.
5. Dragoo JL, Lee RS, Benhaim P, Finerman GA, Hame SL. Relaxin receptors in the human female anterior cruciate ligament. Am J Sports Med. 2003;31(4):577–84.
6. Haase SC, Chung KC. An evidence-based approach to treating thumb carpometacarpal joint arthritis. Plast Reconstr Surg. 2011;127(2):198–25.
7. Owens K, Pearse A, Mason G. Pubic symphysissyndrome. Fetal Maternal Med Rev. 2002;13(2):141–55.
8. Parker EA, Meyer AM, Goetz JE, Willey MC, Westermann RW. Do relaxin levels impact hip injury incidence in women? A scoping review. Front Endocrinol. 2022;13.
9. Em S, Oktagoglu P, Bozkurt M, et al. Serum relaxin levels in benign hypermobility syndrome. J Back Musculoskelet Rehabil. 2015;28(3):473–9.
10. Pokorny MJ, Smith TD, Calus SA, Dennison EA. Self-reported oral contraceptive use and peripheral joint laxity. J Orthop Sports Phys Ther. 2000;30(11):683–92.
11. Wolf J, Scott F, Etchell E, Williams AE, Delaronde S, King KB. Serum relaxin is correlated with relaxin receptors and MMP-1 in the anterior oblique ligament. Osteoarthritis Cartilage. 2012;20(5):250.
12. Wolf JM, Williams AE, Delaronde S, Leger R, Clifton KB, King KB. Relationship of serum relaxin to generalized and trapezial-metacarpal joint laxity. J Hand Surg Am. 2013;38(4):721–8.
13. MacLennan AH. The role of relaxin in human reproduction. Clin Reprod Fertil. 1983;2(2):77–95.
14. Powell BS, Dhauer YY, Szeifler IG. Review of the multiscale effects of female sex hormones on matrix metalloproteinase-mediated collagen degradation. Crit Rev Biomed Eng. 2015;43(5–6):401–28.
15. Wolf JM, Cameron KL, Clifton KB, Owens BD. Serum relaxin levels in young athletic men are comparable with those in women. Orthopedics. 2013;36(2):128–31.
16. O’Byrne EM, Tabachnick M, Anderson LL, Steinetz BG. Characterization of the circulating form of porcine relaxin: biological activity and terminal amino acids. Endocrinology. 1989;124(6):2920–7.
17. Kapila S, Park Y, Ahmad N, Hosomichi J, Hayami T, Tacon C. Mechanisms for Relaxin’s modulation of MMPs and matrix loss in fibrocartilages. Ital J Anat Embryol. 2013;118(1 Suppl):62–5.
18. Kapila S, Xie Y. Targeted induction of collagenase and stromelysin by relaxin in unprimed and β-estradiol-primed diarthrodial joint fibrocartilaginous cells but not in synoviocytes. Lab Invest. 1998;78(8):925–38.
19. Weiss M, Nagelschmidt M, Struck H. Relaxin and collagen metabolism. Horm Metab Res. 1979;11(6):408–10.
20. Goldsmith LT, Weiss G, Steinetz BG. Relaxin and its role in pregnancy. Endocrinol Metab Clin North Am. 1995;24(1):171–86.
21. Nose-Ogura S, Yoshino Q, Yamada-Nomoto K, et al. Oral contraceptive therapy reduces serum relaxin-2 in elite female athletes. J Obstet Gynaecol Res. 2017;43(3):530–5.
22. Samuelson K, Balk EM, Sevetson EL, Fleming BC. Limited evidence suggests a protective association between oral contraceptive pill use and anterior cruciate ligament injuries in females: a systematic review. Sports Health. 2017;9(6):498–510.
23. Anderson T, Shultz SJ, Kincaid Z, et al. Capturing detectable relaxin concentrations in eumenorrheic non-pregnant women. Women Sport Phys Act. 2019;27(1):30–6.
24. Bryant-Greenwood GD, Greenwood FC. The physiology of relaxin. Proc Endocr Soc Aust. 1979;22.
25. Bryant-Greenwood GD, Mercado-Simmen R, Yamamoto SY, Atakaki RF, Uchima FD, Greenwood FC. Relaxin receptors and a study of the physiological role of relaxin. Adv Exp Med Biol. 1982;143:289–314.
26. Alvesode Oliveira J, Marques Simk V, Gon Aalves TS, Soares Reis Vilanova L, Maria Bovi Aubrosano G, Rodrigues Garcia RCM. Female hormones fluctuation and chewing movement of patients with disc displacement. Revista Odonto Ciencia. 2012;27(1):20–5.
27. Arnold C, Van Bell C, Rogers V, et al. The relationship between serum relaxin and knee joint laxity in female athletes. Orthopedics. 2002;25(6):669–73.
28. Bonaventure J, de La Tour B, Tsagris L, Eddie LW, Tregear G, Corvol MT. Effect of relaxin on the phenotype of collagen syntheses by cultured rabbit chondrocytes. Biochim Biophys Acta. 1988;972(2):209–20.
29. Brophy RH, Silvers HJ, Mandelbaum BR. Anterior cruciate ligament injuries: Etiology and prevention. Sports Med Arthrosc Rev. 2010;18(1):2–11.
30. Freeman BM, Mountain DJ, Brock TC, et al. Low testosterone elevation and knee joint laxity in women. J Orthop Sports Phys Ther. 2017;47(2):115–7.
31. Hemmi H, Endo T, Nagasaki K, et al. Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone–induced polyvalent ovary in rats. Biol Reprod. 2001;64(4):157–62.
32. Grossman J, Framehan WH. Relaxin: a new approach for the treatment of acute congestive heart failure. Cardiol Rev. 2010;18(6):305–12.
33. Klein A, Bubisberg SC. Synovial membrane receptors as therapeutic targets: A review of receptor localization, structure, and function. J Orthop Res. 2017;35(8):1589–605.
34. Ando H, Moriwaki C. Studies on relaxin assay with x-ray photography. Endocr J. 1960;7:167–70.
35. Galey S, Konieczko EM, Arnold CA, Cooney TE. Immunohistological detection of relaxin binding to anterior cruciate ligaments. Orthopedics. 2003;26(12):1201–4.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.